Table 2.

ΔC_T for cyclin D3, IL-2, and IFN-γ in PBMC treated with pharmacological inhibitors

	CT		ΔCT	CT		ΔCT	CT		ΔCT
	Cyclin D3	GAPDH		IL-2	GAPDH		IFN-γ	GAPDH
Medium	32.89±0.05	20.32±0.03	12.60±0.04	32.77±0.02	21.65±0.05	11.10±0.05	31.44±0.02	22.17±0.06	9.20±0.05
Medium+PHA	24.88±0.02	21.59±0.01	3.32±0.02	26.32±0.03	21.50±0.04	4.80±0.06	22.65±0.01	20.97±0.10	1.62±0.09
DMSO	33.35±0.12	20.88±0.08	12.36±0.06	32.68±0.04	20.76±0.01	11.88±0.03	31.88±0.02	22.68±0.03	9.19±0.02
DMSO+PHA	24.28±0.03	21.01±0.02	3.30±0.03#	26.44±0.01	21.55±0.02	4.91±0.02#	21.83±0.01	20.32±0.04	1.50±0.03#
PDTC	32.89±0.23	20.07±0.09	12.77±0.15	32.25±0.03	20.35±0.01	11.07±0.02	31.22±0.03	21.98±0.02	9.15±0.03
PDTC+PHA	28.01±0.02	19.87±0.21	8.00±0.10*	30.22±0.06	20.62±0.02	9.53±0.05*	27.43±0.01	21.00±0.06	6.35±0.04*
Cyc A	33.16±0.08	21.05±0.02	12.05±0.05	32.78±0.02	20.88±0.03	11.50±0.02	31.06±0.02	22.01±0.02	9.00±0.02
Cyc A+PHA	30.05±0.01	20.88±0.01	9.12±0.01*	30.10±0.01	21.00±0.01	9.10±0.01*	28.01±0.01	21.07±0.05	6.90±0.04*
U0126	33.65±0.03	21.07±0.01	12.32±0.02	32.48±0.05	21.07±0.04	11.35±0.04	31.55±0.02	21.56±0.04	9.90±0.04
U0126+PHA	29.46±0.02	20.08±0.11	8.49±0.06*	30.89±0.01	20.92±0.02	9.83±0.02*	28.42±0.05	21.60±0.05	6.78±0.05*

Abbreviations: DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IFN, interferon; PBMC, human peripheral blood mononuclear cells; PHA, phytohemagglutinin.

PBMC (5 × 10⁶ cells) were cultured with PDTC (25 μM), cyclosporin A (Cyc A; 2 μM),or U0126 (12.5 μM) in the presence or absence of PHA for 18 h. The cDNA was reverse-transcribed from cellular RNA and amplified by TaqMan PCR assay with an ABI prism 7700 sequence detection system. Each ΔC_T was calculated by subtracting the C_T of GAPDH mRNA from the C_T of cyclin D3, IL-2 or IFN-γ mRNAs, respectively. The representative data from 3 independent experiments with PBMC from different individuals are shown.

^#P<0.01, as compared with DMSO group;

^*P<0.01, as compared with the DMSO+PHA group.